Jamaican ackee processors reported a shortage of can lids during the 2026 harvest, showing how an abundant crop can fail to become exportable food. The Gleaner reported on 12 August that Stanmark Processors had sent more than 100 workers home and curtailed operations while fruit awaited processing. Industry representatives described strong overseas demand despite the disruption.1
Restoring packing capacity is only part of reaching American buyers. The US Food and Drug Administration's current ackee import alert requires scrutiny of processing controls before firms can obtain relief from detention without physical examination. That rule applies across raw, frozen, canned and other ackee products, making safe processing central to access rather than an optional choice of presentation.2
A processor must demonstrate control of the toxin
FDA's compliance guidance identifies hypoglycin A, a naturally occurring toxin, as the concern. It treats levels above 100 parts per million in finished ackee products as evidence of improper processing and grounds for recommending import refusal or seizure. The guidance highlights the selection of naturally ripened fruit and proper cleaning among the processing issues that can affect the result.3
The import alert provides a staged route to market. A foreign facility first petitions to join the yellow list, supplying evidence of its controls. Listed firms can export subject to private laboratory analysis supporting release of each shipment. A firm seeking green-list status must document at least five consecutive entries released by FDA on that basis. Green-list status exempts the specified firm and product from this alert's automatic detention procedure.2
FDA's Spanish explanation of import alerts describes the underlying enforcement power as allowing officials to:4
detener los productos sin examen físico
detain the products without physical examination.4
The explanation says alerts help target risks and can apply to firms, commodities or wider geographical groups. For an exporter, the relevant question is therefore whether its own product and facility satisfy the applicable procedure, rather than whether a competing Jamaican processor already ships successfully.4
Packaging shortages are a separate constraint
The Gleaner's August report attributed the immediate production interruption to the supply of lids for standard ackee cans. It reported Jamaican ackee export earnings of US$18.1 million in 2024, down from US$26.1 million in 2023 following hurricane disruption. Those figures and the reported lay-offs do not establish that FDA rules caused the decline or the factory stoppage. They describe physical constraints alongside the regulatory conditions of an export route.1
Jamaica's trade portal sets out the domestic steps, including an export licence, phytosanitary certification, inspection of packaging facilities and pre-clearance procedures. It specifically tells exporters to meet the destination's requirements on packaging, labelling and shipment. Domestic permissions and American admissibility therefore have to work together for a commercial consignment.5
Nor can processing schedules override the safety threshold. FDA's guidance warns about fruit being forced open before natural ripening and contamination from unsuitable parts of the fruit. The unresolved production question is whether processors can secure packaging and maintain those controls while turning the available harvest into shipments that US authorities will release.3